Skip to main content
StrokeBrain and nervesDrugEarly Phase 1

What this study is

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.

What's being tested

  • Tizanidine

    Intervention · DRUG

    Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.

  • Placebo

    Intervention · DRUG

    Administered as control

Study details

Sponsor
Northwestern University
Conditions
Stroke
Enrolling
64 people
Starts
2024-08-23
Est. completion
2029-07-31
Design
Quadruple-blind, randomized, crossover, Early Phase 1
Record
View on ClinicalTrials.gov ↗